Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$16.57 USD

16.57
466,978

-0.03 (-0.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

KemPharm Posts Positive Top-Line Results on KP415 Prodrug

KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

    Endocyte (ECYT) Soars: Stock Adds 11.4% in Session

    Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

      Biogen Begins Phase III Study on Ischemic Stroke Candidate

      Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.

        Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe

        Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.

          Pacira (PCRX) Rides High on Robust Exparel Performance

          Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

            Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert

            Pacira Pharmaceuticals, Inc. (PCRX) is looking like an interesting pick from a technical perspective

              Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

              Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.

                Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

                Pacira (PCRX) delivered earnings and revenue surprises of 166.67% and 5.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                  What's in Store for Catalyst (CPRX) This Earnings Season?

                  Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.

                    What's in Store for Intrexon (XON) This Earnings Season?

                    Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

                      What's in Store for Epizyme (EPZM) This Earnings Season?

                      Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.

                        Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?

                        On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.

                          AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

                          On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.

                            Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?

                            We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.

                              Aerie (AERI) to Report Q2 Earnings: What's in the Offing?

                              Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.

                                Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

                                Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.

                                  Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                                  In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.

                                    What's in Store for Intercept (ICPT) This Earnings Season?

                                    Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.

                                      What's in Store for Immune Design (IMDZ) in Q2 Earnings?

                                      We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.

                                        Is a Beat in Store for Endocyte (ECYT) This Earnings Season?

                                        The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.

                                          Pacira Focused on Exparel Development Amid Competition

                                          Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

                                            Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

                                            Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

                                              Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?

                                              Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

                                                Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

                                                  Company News For Apr 9, 2018

                                                  Companies in the news are: PSMT,CPB,BWEN,PCRX